Objectives: epidemiological data show growing numbers of patients with Alzheimer´s disease. Cognitive decline and progressive swallowing impairment lead to a significant deterioration of the nutrition status in this population. Early detection and treatment of malnutrition is important for the prognosis of the disease.

Method: a systematic review was conducted. Four databases such as Cochrane, PubMed, Embase and Web of Science were searched by two independent researchers. The inclusion criteria encompass adult patients with diagnosed Alzheimer's disease, studies with screening tools for nutritional assessment such as Mini-Nutritional Assessment and body mass index. Patients without diagnosis or with possible or probable Alzheimer's disease were excluded. Finally, 36 studies with 5293 participants were included to the systematic review. PRISMA protocol was followed when writing this article. Critical Appraisal tools for use in JBI Systematic Reviews were used for quality assessment.

Results: 36 studies were included in this systematic review. More than half of the respondents were from Europe. According to MNA 33.97 % of participants were at risk of malnutrition, 3.74 % malnourished and more than 62 % had proper nutritional status. According to the BMI, nearly 50 % of patients were overweight or obese, 4.22 % had BMI < BMI < 18,49 kg/m2. Risk of malnutrition and malnutrition was diagnosed in 53.8 % and 8.2 % of patients assessed with Mini-Nutritional Assessment - Short Form.

Conclusion: the risk of malnutrition in AD is high, however, significant differences between studies can be observed due to methodological differences. Large epidemiological studies are needed with unified nutritional assessment methods for patients with Alzheimer's disease.

Download full-text PDF

Source
http://dx.doi.org/10.20960/nh.05611DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
16
systematic review
16
nutritional assessment
12
risk malnutrition
12
patients alzheimer's
8
assessment methods
8
mini-nutritional assessment
8
included systematic
8
patients
7
disease
5

Similar Publications

The Glutamate/GABA-Glutamine Cycle: Insights, Updates, and Advances.

J Neurochem

March 2025

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Synaptic homeostasis of the principal neurotransmitters glutamate and GABA is tightly regulated by an intricate metabolic coupling between neurons and astrocytes known as the glutamate/GABA-glutamine cycle. In this cycle, astrocytes take up glutamate and GABA from the synapse and convert these neurotransmitters into glutamine. Astrocytic glutamine is subsequently transferred to neurons, serving as the principal precursor for neuronal glutamate and GABA synthesis.

View Article and Find Full Text PDF

Objectives: epidemiological data show growing numbers of patients with Alzheimer´s disease. Cognitive decline and progressive swallowing impairment lead to a significant deterioration of the nutrition status in this population. Early detection and treatment of malnutrition is important for the prognosis of the disease.

View Article and Find Full Text PDF

Introduction: Alzheimer's disease (AD), a prevalent neurodegenerative disease, is primarily characterized by progressive neuron loss and memory impairment. NOD-like receptors (NLRs) are crucial for immune regulation and maintaining cellular homeostasis. Recently, NLRs have been identified as important contributors to neuroinflammation, thus presenting a potential approach for reducing inflammation and slowing AD progression.

View Article and Find Full Text PDF

Introduction: Ginseng, known as the "king of herbs," has long been used in traditional Chinese medicine due to its beneficial properties, including anti-aging, anti-inflammatory, and anti-apoptotic effects. Ginsenosides, the active compounds in ginseng, have shown promise in treating neurodegenerative diseases such as Alzheimer's disease (AD). This study investigates the therapeutic potential of Ginsenoside Ro and its underlying mechanisms in AD treatment.

View Article and Find Full Text PDF

We examine the relationship between sleep, glymphatics and Alzheimer's disease (AD), and recent work questioning glymphatic clearance during sleep. We highlight a need for understanding glymphatic and/or other mechanism of clearance during sleep, and review glymphatic flow measurement methods. Further, we explore dual orexin receptor antagonists (DORAs) potential to mitigate AD sleep disturbances and enhance clearance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!